High hepatitis C cure rate seen in NIH-led trial of 6-week oral drug regimens

(NIH/National Institute of Allergy and Infectious Diseases) Thirty-eight of 40 volunteers with hepatitis C virus (HCV) infections who received a combination of three direct-acting oral drugs for six weeks were cured in a clinical trial conducted at the National Institutes of Health. A six-week course of therapy is half the length of time previously shown to achieve a similar cure rate using two direct-acting oral HCV drugs only. The trial findings appear in The Lancet.